• Rika devices are installed in more than 300 CSL Plasma centers to increase plasma supply for patients.
• It takes 1,200 plasma donations each year to treat an individual with severe hemophilia, just one of many conditions for which plasma-derived therapies are the primary treatment.¹
• Over 300 million people globally live with one of more than 7,000 rare diseases.²

BOCA RATON, Fla., and LAKEWOOD, Colo. – 18 September 2025 – CSL Plasma and Terumo Blood and Cell Technologies (Terumo BCT) today announced that the Rika^™ Plasma Donation System has been deployed in all CSL Plasma centers across the U.S. — a major milestone in donor care, operational efficiency and access to lifesaving plasma-derived therapies for patients.

“This achievement underscores our commitment to innovation that directly benefits both donors and patients,” said Steve Marlow, general manager and senior vice president at CSL Plasma. “By integrating the Rika system into our operations, we've improved efficiency and the donor experience. Every day, our donors ‘Do the Amazing’ by donating plasma to help those in crucial need of therapies made from plasma.”

Over the past 18 months, Rika systems have been installed in more than 300 CSL Plasma centers. Developed by Terumo BCT, Rika is a next-generation plasma collection platform designed to enhance the donor experience with faster procedures, improved comfort and enhanced collection personalized for each donor.

The system’s advanced automation, including the iNomi^™ Nomogram, tailors collection based on each donor’s hematocrit, weight and height — with an ability of collecting up to 1,000 mL of plasma from eligible donors in less than 35 minutes. With less than 200 mL of blood volume outside the body at any time during the procedure, the system supports enhanced donor comfort and the option to return blood and plasma if a procedure is not completed.

“Rika is transforming plasma donation with individualized care and automation that improves efficiency and comfort,” said Patrick Daly, chief business officer at Terumo Blood and Cell Technologies. “Our partnership with CSL Plasma brings this innovation to scale — making it more comfortable for people to donate and expanding access to critical therapies.”

The Rika system enables a higher yield of plasma donations and reduces time on the donation bed. This allows CSL’s donation centers to collect more efficiently. The increased supply of plasma benefits patients who rely on plasma-derived therapies. These include people with rare and serious conditions — such as immune or bleeding disorders — as well as those needing treatment during childbirth or for burns and trauma in emergency settings.

“Thanks to plasma donors, I’ve been able to live a full life — raising my family, enjoying my grandchildren and staying active well into my seventies. Innovations like Rika make donating faster and more comfortable, which means more people like me can keep living the lives we love,” said Pete Atherton, PhD, who relies on plasma-derived medicine.

It is estimated that there are 300 million people globally who live with one of more than 7,000 rare diseases. This highlights the criticality of getting more plasma from each plasma donation. It takes 1,200 plasma donations each year to treat an individual with severe hemophilia, and that is just one of many conditions for which plasma-derived therapies are the primary method of treatment. As the number of individuals diagnosed with these rare conditions increases, more donations are needed to meet demand.

The nationwide rollout, completed in June, demonstrates a commitment to deploying advanced technology that elevates the donor experience and meets the global demand for plasma-derived medicines.

1. https://www.pptaglobal.org/donate
2. World Health Organization. Seventy-eighth World Health Assembly – daily update: 24 May 2025. First-ever rare diseases resolution underscores equity and inclusion. Accessed September 5, 2025. https://www.who.int/news/item/24-05-2025-seventy-eighth-world-health-assembly---daily-update--24-may-2025.

About Plasma

Plasma, the liquid component of blood, is rich in proteins, antibodies, clotting factors and essential nutrients. These components play a critical role in treating a variety of medical conditions, including trauma, shock, burns and other emergencies. Plasma-derived therapies are particularly valuable in addressing complex health needs, such as those of women and young mothers during pregnancy and delivery. These therapies can also provide lifesaving treatments for a range of chronic and rare conditions, including immune deficiencies, hemophilia, and other bleeding and neurological disorders.

About CSL Plasma

CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with nearly 330 plasma donation centers globally, including in the U.S. and Europe. CSL Plasma is a subsidiary of CSL, a global biopharma company.

Plasma collected at CSL Plasma facilities is used by CSL for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries. This includes people who rely on plasma-derived therapies that treat diseases such as primary immune deficiencies, hereditary angioedema, inherited respiratory disease, hemophilia and other bleeding and neurological disorders.

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 29,000+ people. For more information about CSL Plasma visit, cslplasma.com.

About Terumo Blood and Cell Technologies 

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 160 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. To learn more about Terumo Blood and Cell Technologies visit, www.TerumoBCT.com.

Rika^™ and iNomi^™ are either registered trademarks or trademarks of Terumo BCT, Inc in the United States and/or other countries. See TerumoBCT.com/Trademarks for details.